BioHealth News Archive
Mallinckrodt (MNK) Completes Acquisition Of Sucampo Pharmaceuticals (SCMP)
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has closed the acquisition of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical…
Read More
NIH funding fewer clinical trials, Johns Hopkins study shows – Baltimore Sun
The National Institutes of Health has been funding fewer clinical trials in recent years, according to new Johns Hopkins University research. {iframe}http://www.baltimoresun.com/health/bs-hs-nih-clinical-trials-20180213-story.html{/iframe}
Read More
PIERIS PHARMACEUTICALS ANNOUNCES PRICING OF ITS PUBLIC OFFERING
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases,…
Read More
Please join the BioPark’s Monthly Networking Event
Host: UM BioPark & Wexford Science + Technology Location: UM BioPark The Nook Cafe 801 W. Baltimore Street Baltimore Maryland 21201 Time: Thursday, February 22, 2018 5:00pm…
Read More
Dr. Richard Douglas Joins MaxCyte Board
MaxCyte, the global cell-based medicines and technology company, announces that 30-year life sciences industry veteran Richard Douglas, Ph.D., has been appointed to the Company’s Board of Directors as an Independent Non-Executive Director. {iframe}https://www.maxcyte.com/richard-douglas-joins-board/{/iframe}
Read More
A New Material Called “Superwood” Is Just As Strong As Steel
Is wood the next advanced material? Scientists at the University of Maryland reported last week that they’ve discovered a way to treat wood to make…
Read More
NextGen Venture Partners Joins Brown Advisory
Brown Advisory—an investment and strategic advisory firm committed to making a material and positive difference in the lives of its clients—is excited to join…
Read More
ABL Europe and SillaJen Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies – ABL, Inc.
SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and ABL Europe, an ABL, Inc. company…
Read More
Researchers Develop Breakthrough Technique to Combat Cancer Drug Resistance – Fischell Department of Bioengineering
The ability for cancer cells to develop resistance to chemotherapy drugs – known as multidrug resistance – remains a leading cause for tumor recurrence…
Read More
11 Startups with JHTV Ties Rank Among Baltimore’s Best – JHTV
In the last six months, Personal Genome Diagnostics (PGDx) raised a $75 million series B, Harpoon Medical sold for $100 million and Sunayu acquired…
Read More
Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines
Lonza Pharma & Biotech and Denali Therapeutics (NASDAQ: DNLI) announced today an exclusive strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases. The…
Read More
Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting (NYSE:RNN)
Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced that updated safety and…
Read More
The University of Maryland is getting a new $50 million engineering building – The Diamondback
The University System of Maryland Board of Regents voted on Friday to approve the construction of a new engineering facility on the University of…
Read More
Shepherd Entrepreneurship and Research Corporation achieves nonprofit status | News, Sports, Jobs – Journal News
Shepherd University has created a new nonprofit organization with a mission of helping facilitate research, innovation, and entrepreneurship. On January 24, the Internal Revenue…
Read More
New report highlights New York City’s health tech and life science investment landscape – MedCity News
By StartUp Health’s reckoning, New York City was the second most active city for health tech dealflow in 2017 with $1 billion invested across 63…
Read More